Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

A new version called “Ocrevus Zunovo” was recently approved by the Food and Drug Administration and is reportedly much quicker to inject. “Not everybody has the luxury of being able to spend ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Of the three types of MS, PPMS is considered the rarest, affecting 10% of people living with MS. As with other forms of MS, ...

Granted, Ocrevus Zunovo is a very large volume subcutaneous version of the drug that requires 10 minutes to administer, and the whole process takes about 55 minutes after the first dose ...

Dubbed Ocrevus Zunovo, the under-the-skin version of the blockbuster CD20 antibody drug could represent an additional CHF 2 billion sales opportunity, Graham said during the investor call.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Lee-Ballou was initially denied twice by her insurance provider for Ocravus Zunovo. That’s when Genentech ... As the availability of Ocrevus Zunuvo continues to increase across the country ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

The FDA also approved Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for patients with relapsing and progressive multiple sclerosis. The European Commission ...